Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 and up

Thiazide diuretics to lower blood pressure in people on peritoneal dialysis

Official title: Blood Pressure Control With Thiazide Diuretics in Peritoneal Dialysis Patients

Run by Chinese University of Hong Kong · NCT07271420 · Data updated 2026-11-12

This trial will try a daily 25 mg hydrochlorothiazide pill to lower blood pressure in people on peritoneal dialysis whose blood pressure is above 140/90.

More Hypertension trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment40 (estimated)
SponsorChinese University of Hong Kong
Academic / other
Locations1 site (Hong Kong)
StatusRecruiting
StartedJanuary 1, 2020
Main results expectedDecember 31, 2026
Study endsJune 30, 2027
Registry record updatedDecember 9, 2025
Trial IDNCT07271420 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults on chronic peritoneal dialysis with uncontrolled hypertension (SBP >140 mmHg and/or DBP >90 mmHg) who can attend the Hong Kong study site and are not scheduled for dialysis change or transplant within three months.

Probably not a fit

Patients without meaningful residual renal function, those with life expectancy under three months, or those planning to switch to hemodialysis or undergo transplantation soon are unlikely to benefit from this approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-center treatment-withdrawal crossover trial enrolling 10 chronic peritoneal dialysis patients with uncontrolled hypertension. Participants receive hydrochlorothiazide 25 mg once daily in addition to their usual care for 90 days, followed by a 14-day washout and a 90-day control period. Blood pressure changes (systolic and diastolic) are tracked to compare the on-treatment and off-treatment periods. The study excludes patients with very limited life expectancy or those planning conversion to hemodialysis or kidney transplant within three months.

Why it matters

Potential benefit: If successful, adding hydrochlorothiazide could improve blood pressure control and potentially reduce cardiovascular risk in peritoneal dialysis patients with some residual kidney function.

How similar studies have gone: Prior data are limited and mixed; small studies and clinical experience suggest thiazides can lower blood pressure when residual renal function exists, but robust evidence in peritoneal dialysis patients is sparse.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients on chronic peritoneal dialysis, with uncontrolled hypertension (SBP \>140 mmHg and/or DBP \>90 mmHg)

Exclusion Criteria:

* Patients with a life expectancy of less than 3 months, planned conversion to hemodialysis, or scheduled kidney transplantation within 3 months

Where it's running

  • Prince of Wales Hospital. The Chinese University of Hong Kong
    Hong Kong, Hong Kong
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.